What do systematic reviews say?

Standard rhGH vs no treatment

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 94 participants
  Very low

High‐dose rhGH vs placebo

High‐dose rhGH showed no clear difference in number of pulmonary exacerbations or hospitalisations compared with placebo (low certainty).

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  RR 1.92 [0.66, 5.61]
  1 study · 42 participants
  Low

High‐dose rhGH vs standard‐dose rhGH

High‐dose rhGH showed no clear difference in number of pulmonary exacerbations or hospitalisations compared with standard‐dose rhGH (low certainty).

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  RR 1.28 [0.52, 3.18]
  1 study · 42 participants
  Low

Standard rhGH vs placebo

Standard rhGH showed no clear difference in number of pulmonary exacerbations or hospitalisations compared with placebo (low certainty).

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  RR 1.5 [0.49, 4.59]
  1 study · 44 participants
  Low

Summary of findings: levofloxacin for inhalation solution vs tobramycin

Summary of findings: levofloxacin for inhalation solution leads to lower pulmonary exacerbations: number of hospitalisations due to… compared with tobramycin (high certainty).

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  RR 0.62 [0.4, 0.98]
  1 study · 282 participants
  High